Seattle Genetics was founded in 1998 by a great team of scientists including its current president and chief executive officer, Clay B. Siegall, Ph.D. It’s known for its extensive research on developing clinical and preclinical products which target various forms of cancer and auto immune diseases. The company, through the leadership of Dr.Siegell has managed to lead in the development of antibody-drug conjugates which have proven very effective in the treatment of cancer. The company’s headquarters are in Bothel, Washington.
The Chief Executive Officer
Dr. Clay Siegall was among the founding fathers of Seattle Genetics and is currently serving as the company president and chief executive officer. Together with that, the doctor is in the board of directors of two private pharmaceutical companies. His capital-raising skills came to play when he managed to secure Seattle Genetics an impressive funding of more than $600 million from both public and private sources.
Educational Background and Previous Work
Dr. Siegall has a Ph.D. in Genetics from George Washington University and graduated with a B.S. in Zoology from the University of Maryland. his passion in cancer research have become the backbone of his career as he strives to spearhead development of effective ADC’s, 7 of which are under advanced clinical-stage programs. Dr. Siegall previously worked for the Bristol-Myers Squibb Pharmaceutical Research Institute for 6 years and the National Cancer Institute for 3 years. Throughout his life, Dr.Clay managed to author 70 publications and currently holds 15 patents.
Seattle Genetics has close to 650 employees all across America. Besides leading in development of antibody technologies, the company has entered into numerous strategic partnerships. The partnerships include an exclusive collaboration with Genentech for SGN-40 prized at almost $860. Some other ADC collaborations with MedImmune, CuraGen, Bayer and Progenics have generated more an income of approximately $70 million.
The company developed ADCETRIS, a first in a new class of ADCs that has successfully treated over 15,000 cancer patients all over the world. The drug got approved way back in 2011 by the Food and Drug Administration Board (FDA).
The company’s technology also empowers more than 20 ADC’s which are currently still in clinical development.
Seattle Genetics is currently working on two new ADC’s that will go a long way in treating acute myeloid leukemia to ensure survival of patients’ diagnosed with it.